3 New HCV Article Summaries

[Guest guest]

HIVandHepatitis.com

e-Newsletter for Friday, January 14, 2011

HCV Protease Inhibitor Boceprevir Accepted for Priority Review in U.S. and

Europe

SUMMARY› Merck announced last week that the U.S. Food and Drug Administration

(FDA) and the European Medicines Agency have both agreed to priority or

accelerated review for boceprevir, an experimental hepatitis C virus (HCV)

protease inhibitor currently in Phase 3 clinical trials. Along with Vertex's

telaprevir, these first direct-acting oral agents are expected to usher in a new

paradigm for chronic hepatitis C treatment.

Company Collaboration to Test BMS-790052 + PSI-7977 Combo for Hepatitis C

SUMMARY› Bristol-Myers Squibb and Pharmasset recently announced that they will

collaborate to conduct clinical testing of a combination direct-acting hepatitis

C treatment regimen consisting of the HCV NS5A inhibitor BMS-790052 plus the

nucleotide HCV polymerase inhibitor PSI-7977. The companies will test all-oral

regimens with and without ribavirin in previously untreated patients.

Peregrine Starts Phase 2 Trial of Monoclonal Antibody Hepatitis C Treatment

SUMMARY› Peregrine Pharmaceuticals this week announced the start of a Phase 2

clinical trial to test a novel approach to hepatitis C virus (HCV) treatment

using the monoclonal antibody bavituximab. The antibody -- which is also under

study as a cancer chemotherapy -- works by binding to host cells infected with

HCV, HIV, and certain other viruses, triggering an immune system attack. It will

be studied in combination with ribavirin in previously untreated genotype 1

chronic hepatitis C patients.

HCV Main Section

[Guest guest]

HIVandHepatitis.com

e-Newsletter for Friday, January 14, 2011

HCV Protease Inhibitor Boceprevir Accepted for Priority Review in U.S. and

Europe

SUMMARY› Merck announced last week that the U.S. Food and Drug Administration

(FDA) and the European Medicines Agency have both agreed to priority or

accelerated review for boceprevir, an experimental hepatitis C virus (HCV)

protease inhibitor currently in Phase 3 clinical trials. Along with Vertex's

telaprevir, these first direct-acting oral agents are expected to usher in a new

paradigm for chronic hepatitis C treatment.

Company Collaboration to Test BMS-790052 + PSI-7977 Combo for Hepatitis C

SUMMARY› Bristol-Myers Squibb and Pharmasset recently announced that they will

collaborate to conduct clinical testing of a combination direct-acting hepatitis

C treatment regimen consisting of the HCV NS5A inhibitor BMS-790052 plus the

nucleotide HCV polymerase inhibitor PSI-7977. The companies will test all-oral

regimens with and without ribavirin in previously untreated patients.

Peregrine Starts Phase 2 Trial of Monoclonal Antibody Hepatitis C Treatment

SUMMARY› Peregrine Pharmaceuticals this week announced the start of a Phase 2

clinical trial to test a novel approach to hepatitis C virus (HCV) treatment

using the monoclonal antibody bavituximab. The antibody -- which is also under

study as a cancer chemotherapy -- works by binding to host cells infected with

HCV, HIV, and certain other viruses, triggering an immune system attack. It will

be studied in combination with ribavirin in previously untreated genotype 1

chronic hepatitis C patients.

HCV Main Section

[Guest guest]

HIVandHepatitis.com

e-Newsletter for Friday, January 14, 2011

HCV Protease Inhibitor Boceprevir Accepted for Priority Review in U.S. and

Europe

SUMMARY› Merck announced last week that the U.S. Food and Drug Administration

(FDA) and the European Medicines Agency have both agreed to priority or

accelerated review for boceprevir, an experimental hepatitis C virus (HCV)

protease inhibitor currently in Phase 3 clinical trials. Along with Vertex's

telaprevir, these first direct-acting oral agents are expected to usher in a new

paradigm for chronic hepatitis C treatment.

Company Collaboration to Test BMS-790052 + PSI-7977 Combo for Hepatitis C

SUMMARY› Bristol-Myers Squibb and Pharmasset recently announced that they will

collaborate to conduct clinical testing of a combination direct-acting hepatitis

C treatment regimen consisting of the HCV NS5A inhibitor BMS-790052 plus the

nucleotide HCV polymerase inhibitor PSI-7977. The companies will test all-oral

regimens with and without ribavirin in previously untreated patients.

Peregrine Starts Phase 2 Trial of Monoclonal Antibody Hepatitis C Treatment

SUMMARY› Peregrine Pharmaceuticals this week announced the start of a Phase 2

clinical trial to test a novel approach to hepatitis C virus (HCV) treatment

using the monoclonal antibody bavituximab. The antibody -- which is also under

study as a cancer chemotherapy -- works by binding to host cells infected with

HCV, HIV, and certain other viruses, triggering an immune system attack. It will

be studied in combination with ribavirin in previously untreated genotype 1

chronic hepatitis C patients.

HCV Main Section

[Guest guest]

HIVandHepatitis.com

e-Newsletter for Friday, January 14, 2011

HCV Protease Inhibitor Boceprevir Accepted for Priority Review in U.S. and

Europe

SUMMARY› Merck announced last week that the U.S. Food and Drug Administration

(FDA) and the European Medicines Agency have both agreed to priority or

accelerated review for boceprevir, an experimental hepatitis C virus (HCV)

protease inhibitor currently in Phase 3 clinical trials. Along with Vertex's

telaprevir, these first direct-acting oral agents are expected to usher in a new

paradigm for chronic hepatitis C treatment.

Company Collaboration to Test BMS-790052 + PSI-7977 Combo for Hepatitis C

SUMMARY› Bristol-Myers Squibb and Pharmasset recently announced that they will

collaborate to conduct clinical testing of a combination direct-acting hepatitis

C treatment regimen consisting of the HCV NS5A inhibitor BMS-790052 plus the

nucleotide HCV polymerase inhibitor PSI-7977. The companies will test all-oral

regimens with and without ribavirin in previously untreated patients.

Peregrine Starts Phase 2 Trial of Monoclonal Antibody Hepatitis C Treatment

SUMMARY› Peregrine Pharmaceuticals this week announced the start of a Phase 2

clinical trial to test a novel approach to hepatitis C virus (HCV) treatment

using the monoclonal antibody bavituximab. The antibody -- which is also under

study as a cancer chemotherapy -- works by binding to host cells infected with

HCV, HIV, and certain other viruses, triggering an immune system attack. It will

be studied in combination with ribavirin in previously untreated genotype 1

chronic hepatitis C patients.

HCV Main Section